MedPath

Bleomycin

Bleomycin for Injection, USP

Approved
Approval ID

e629ba5a-4e08-4249-9551-af6dbd98a7e4

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Aug 25, 2022

Manufacturers
FDA

Hospira, Inc.

DUNS: 141588017

Products 2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

BLEOMYCIN

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code0409-0332
Application NumberANDA065031
Product Classification
M
Marketing Category
C73584
G
Generic Name
BLEOMYCIN
Product Specifications
Route of AdministrationINTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS, INTRAPLEURAL
Effective DateAugust 25, 2022
FDA Product Classification

INGREDIENTS (3)

SULFURIC ACIDInactive
Code: O40UQP6WCF
Classification: IACT
BLEOMYCIN SULFATEActive
Quantity: 15 [USP'U] in 1 1
Code: 7DP3NTV15T
Classification: ACTIM
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT

BLEOMYCIN

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code0409-0323
Application NumberANDA065031
Product Classification
M
Marketing Category
C73584
G
Generic Name
BLEOMYCIN
Product Specifications
Route of AdministrationINTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS, INTRAPLEURAL
Effective DateAugust 25, 2022
FDA Product Classification

INGREDIENTS (3)

BLEOMYCIN SULFATEActive
Quantity: 30 [USP'U] in 1 1
Code: 7DP3NTV15T
Classification: ACTIM
SULFURIC ACIDInactive
Code: O40UQP6WCF
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.